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Aim: Primary testicular lymphoma (PTL) is an uncommon and aggressive form of extranodal non-Hodgkin’s lymphoma (NHL). 
We aimed to analyse the clinicopathological characteristics and outcomes of our PTL cases. Materials and Methods: A review was 
made of the medical records of 339 NHL patients who were treated in the Medical Oncology Department between January 2005 and 
December 2013. Results: 8 PTL patients were identified from the 339 NHL patients. The average age of the patients was 
67.7 ± 7.9 years (range 53–79 years). The mean follow-up time was 24.8 months (range 7–98 months). Inguinal orchiectomy was 
performed as a diagnostic and initial therapy and all the patients underwent 4–6 cycles of chemoimmunotherapy consisting of cy-
clophosphamide, doxorubicin, vincristine and prednisone plus rituximab. 4 of 8 patients received intrathecal prophylactic chemo-
therapy and 6 of 8 patients continued contralateral testis irradiation. Relapse occured in only 1 patient in central nervous system 
after 6 months who had not received intrathecal prophylaxis. No contralateral testis relapse was observed. Conclusions: Primary 
testicular NHL is an uncommon entity and we evaluated 8 patients; with one relapse in central nervous system and no relapse 
in the contralateral testis.
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Non-Hodgkin’s lymphoma (NHL) is a common dise-
ase and nearly 30% of cases occur in extranodal sites. 
Primary testicular lymphoma (PTL) is an uncommon and 
aggressive form of extranodal NHL [1, 2]. It accounts 
for less than 5% of testicular malignancies and 1–2% 
of NHL cases, although it is the most common testicular 
malignancy in men aged > 60 years [1, 3]. PTL is usually 
characterized by the unilateral mass or swelling of testis 
and synchronous bilateral involvement at presentation 
occurs in 6–10% of patients [4, 5].
Histopathologically, diffuse large B-cell lym-
phoma (DLBCL) is the predominant type in more than 
80% of PTL cases [1]. Clinically they do not display 
the clear survival plateau of other high-grade lympho-
mas because of the occurrence of late relapses [1, 
4, 6]. Relapse presents mostly in extranodal sites, 
especially in the central nervous system (CNS) and 
contralateral testis [7]. Both these sites are considered 
as immunoprivileged sites, owing to the blood-brain 
and blood-testis barrier which reduces the penetra-
tion of chemotherapy agents as lymphoma cells may 
escape the host T-cell antitumour response [8–10].
PTL is a rare condition and prospective randomised 
controlled trials have been difficult to establish, 
so standard treatments for PTL have not been well 
defined. Orchiectomy is indicated for both diagnostic 
and therapeutic purposes but prognosis is considered 
to be poor in patients treated with only orchiectomy 
and/or radiation [4, 11]. Recently combined modality 
treatment with rituximab plus doxorubicin-based che-
motherapy, prophylactic intrathecal chemotherapy, 
and scrotal radiotherapy is recommended, but con-
troversies still exist.
In this retrospective study, it was aimed to analyse 
the clinicopathological characteristics and outcomes 
of 8 PTL cases and discuss the knowledge and experi-
ence gained in this rare but important entity.
PATIENTS AND METHODS
A review was made of the medical records 
of 339 NHL patients who were treated in the Medical 
Oncology Department between January 2005 and 
December 2013. Eight of the 339 patients were PTL. All 
PTL patients underwent orchiectomy for pathologi-
cal diagnosis. The Ann Arbor classification system 
was used for staging and B symptoms included night 
sweats, recurrent fever and unexplained 10% loss 
of body weight within 6 months. The international 
prognostic index (IPI) score was also determined.
Complete remission (CR) was defined as absence 
of disease signs and symptoms one month after 
completion of all treatments. The overall survival (OS) 
duration was calculated from the time of diagnosis 
to the time of death or to the last follow-up. Progres-
sion-free survival (PFS) was measured from the time 
of diagnosis to the time of treatment failure, relapse, 
or death because of lymphoma. Relapse was defined 
as the appearance of a new lesion in a patient with CR.
Statistical analyses were performed with SPSS soft 
ware (SPSS 15.0, Chicago, IL). Descriptive analyses 
were used for the characteristics of the study popula-
tion. Survival analysis was applied with the Kaplan — 
Meier method.
RESULTS
Between January 2005 and December 2013 8 PTL 
patients were identified from the 339 NHL patients. 
The average age of the patients was 67.7 ± 7.9 years 
(range 53–79 years). The mean follow-up time was 
24.8 months (range 7–98 months). 4 patients had PTL 
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in the right testicle and 4 patients had PTL in the left 
testicle. 6 patients were Ann Arbor stage I or II at the time 
of diagnosis and 2 patients were stage III. Only 1 patient 
had B symptoms at stage III. Inguinal orchiectomy was 
performed as a diagnostic and initial therapy and DLBCL 
was confirmed in all 8 patients after histopathological 
examination. After orchiectomy, all the patients under-
went 4–6 cycles of chemoimmunotherapy consisting 
of cyclophosphamide, doxorubicin, vincristine and 
prednisone (CHOP) plus rituximab (R), followed by in-
trathecal prophylactic chemotherapy in 4 of 8 patients 
and irradiation of the contralateral testis in 6 of 8 pa-
tients. CR was achieved in 7 patients after R-CHOP 
chemotherapy, 1 patient was still undergoing chemo-
therapy during the last follow-up with partial response 
(patient # 2) and 1 patient was continuing chemotherapy 
and planned contralateral testis irridation (patient # 8). 
During the follow-up period, a relapse occured in only 
1 patient (patient # 4) in the CNS after 6 months, and 
it was determined that he had not received CNS prophy-
laxis. He was treated only with palliative radiotherapy. 
No contralateral testis relapse was observed. The pa-
tient characteristics and follow-up data are presented 
in Table. Figure shows the OS analysis of the PTL cases.
Table. Epidemiological features, clinicopathological characteristics, type 
of management, and outcome of patients with PTL
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1 53 IE 1 Left Orchiectomy 4 × R-CHOP + − CR − 98 +
2 73 IIIEB 4 Left Orchiectomy 4 × R-CHOP − − PR − 7 +
3 63 IIIE 4 Right Orchiectomy 6 × R-CHOP + + CR − 9 +
4 68 IIE 2 Right Orchiectomy 6 × R-CHOP + - CR +(6) 12 −
5 79 IE 1 Right Orchiectomy 4 × R-CHOP + - CR − 15 +
6 66 IIE 1 Right Orchiectomy 6 × R-CHOP + + CR − 36 +
7 74 IIE 1 Left Orchiectomy 6 × R-CHOP + + CR − 14 −
8 66 IE 1 Left Orchiectomy 6 × R-CHOP − − CR − 8 +
Note: R-CHOP — rituximab, cyclophosphamide, doxorubicin, vincristine, and 
prednisone; RT — radiotherapy; PR — partial remission. 
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Figure. Kaplan — Meier OS curve for PTL patients
DİSCUSSİON
In this study, the clinicopathological characteristics 
and outcomes of 8 PTL cases treated at our depart-
ment have been reported. In a recent report, Mertsoylu 
et al. [12] evaluated 802 NHL patients and found only 
2 cases of PTL in Southern Turkey. In an other study 
from South India, Padhi et al. [13] reported 2 PTL pa-
tients among 308 NHL cases. Differently we treated 
more PTL patients in our department.
PTL is a rare and aggressive form of extranodal NHL 
which accounts for 1–2% of NHL cases in men aged 
> 60 years [1, 3]. Although outcomes for patients with 
PTL have historically been poor with no plateau in PFS 
and OS curves, significant improvements have been 
achieved with the addition of radiotherapy (RT) to full-
course anthracycline-based chemotherapy, R and 
CNS-directed prophylaxis [14]. Relapses frequently 
occur in the contralateral testis and CNS [15]. Both 
these sites are considered to be immunoprivileged 
sites, where lymphoma cells may escape the host 
T-cell antitumour response and chemotherapy may 
have reduced efficacy because of the mechanical 
blood testis barrier and blood brain barrier [8, 9]. 
In addition, low levels of p53 expression but high levels 
of phosphorylated STAT3 (pSTAT3), overexpression 
of pCXCR4, and upregulation of the nuclear factor kB 
(NF-kB) pathway were detected in PTL cases by Menter 
et al. [16] and they reported that expression of both 
CXCR4 and pCXCR4 was predictive of inferior PFS. Pre-
clinical studies have reported that directed metastasis 
is mediated by CXCR4 activation and migration toward 
CXCR12-expressing target organs [14, 17]. Therefore, 
CXCR4 overexpression may predispode extranodal re-
lapse in PTL. Due to the above-mentioned mechanisms 
orchiectomy alone is not sufficient even in the early 
stages. It has been observed that more than 60% of pa-
tients treated with simple orchiectomy relapsed mostly 
in the CNS in the first five years [4, 18].
In the current study, histopathologically all the pa-
tients were DLBCL, which was consistent with other 
reports [19–21]. The most common regimen reported 
in retrospective studies is R-cyclophosphamide, 
doxorubicin, vincristine and prednisolone 3 weekly 
(R-CHOP-21) and there are no data to suggest 
that any alternative regimen offers a better out-
come [3, 7, 22]. In our study, all the PTL patients 
received  R-CHOP. R is a monoclonal antibody against 
the CD20 antigen expressed on the majority of B-cell 
lymphomas which has improved the outcome of both 
high- and low-grade B-cell lymphomas in general. 
It has also been incorporated into treatment strategies 
for PTL over the last decade. However, a retrospec-
tive analysis of 769 patients with testicular lymphoma 
from the Surveillance, Epidemiology and End Result 
database in the USA did not show any improve-
ments in disease-specific survival after 2000, when 
R came into common usage [4]. In a randomized trial 
of 399 patients with DLBCL by Feugier et al. [23] the ef-
fect of CHOP plus R (R-CHOP) was compared with that 
of CHOP and it was shown that the addition of R did not 
reduce the risk of dissemination to the CNS at relapse. 
According to the results of these retrospective studies, 
the International Extranodal Lymphoma Study Group 
(IELSG) reported a prospective phase II trial [24], 
in which 53 patients received CHOP-21 plus R followed 
by prophylactic irradiation of the contralateral testis 
and intrathecal chemotherapy prophylaxis of 4 doses 
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of methotrexate. The patients with stage II disease 
also received involved-field RT. After a median follow-
up of 65 months, the 5-year PFS and OS rates were 
74% and 85%, respectively. Only 3 cases demonstra-
ted CNS relapse and no cases demonstrated relapse 
in the contralateral testis.
In the current series, relapse occured in only 1 pa-
tient in CNS after 6 months who had not received CNS 
prophylaxis and he died from his disease 6 months 
after this relapse. The second patient died because 
of myoardial infarction 14 months after the diagnosis.
Similar to the IELSG study no contralateral testis 
relapse was observed in the current study group. 
Neither was any CNS relapse observed in those who 
received intratechal methotrexate but the current study 
population was small and the follow-up period was not 
long enough for some patients.
As CNS prophylaxis after anthracycline-based com-
bined chemotherapy and RT, Aviles et al. [25] treated 
34 PTL patients with high-dose methotrexate (6 g/m2). 
More recently Lokesh et al. [26] reported their PTL 
series but none of them received CNS prophylaxis nor 
contrlateral testis irradiation so the survival is poor. 
In an other new report Ichikawa et al. [27] confirmed 
that combined modality treatment suggests a better 
PSF similar to our findings.
On the other hand, new potential therapeutic ap-
proaches are necessary because of the poor prognosis 
for relapsed patients especially in CNS. If CXCR4 is found 
to have a pathophysiologic role in mediating extrano-
dal relapse, development of the CXCR4 inhibitor may 
prove attractive as a therapeutic adjuvant to chemo-
therapy. In addition, overactivation of the NF-kB and 
STAT3 signalling pathways may be exploited as a tar-
get, but rigorous testing is required in prospective 
clinical trials in PTL patients.
In conclusion, PTL is a rare condition and prospec-
tive randomised controlled trials have been difficult 
to establish. However, collective international experi-
ence based on a number of retrospective analyses has 
led to the evolution of therapeutic protocols that offer 
a significantly improved prognosis for PTL. The best 
outcome is achieved from combined treatment with 
orchiectomy, R-CHOP and CNS prophylaxis with in-
trathecal chemotherapy and irradiation of the contra-
lateral testis. Despite notable improvement in the PFS 
and OS, CNS relapse remains a devastating condition. 
Ongoing IELSG30 phase II trials with modified CNS 
prophylaxis (intrathecal injections of cytarabine) could 
yield essential information. In the future, the develop-
ment of biological therapeutic agents should be con-
sidered for this rare but aggressive disease.
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